Cancer Science · Nov 16, 2026

Gut Bacteria‐Derived Colibactin as a Driver of Early‐Onset Colorectal Cancer

By Shiba S, Yachida S, Shibata T

Colorectal cancer (CRC) remains a global threat that has yet to be conquered, and this challenge is compounded by the rising worldwide incidence of early‐onset CRC (EO‐CRC), diagnosed before age 50. Most EO‐CRC cases are sporadic and microsatellite‐stable, and their etiology has yet to be fully elucidated. “Mutational epidemiology,” which applies whole‐genome sequencing to decode mutational signatures imprinted in tumor genomes, has emerged as a powerful tool for tracing carcinogen exposures. A key discovery is colibactin, a genotoxic metabolite produced by Escherichia coli and other Enterobacteriaceae carrying the pks pathogenicity island, which generates unique mutational signatures, SBS88 and ID18. Large‐scale CRC genomic surveys, including the Mutographs Cancer Grand Challenge, show that regions with higher CRC incidence carry greater colibactin‐signature burden, and that Japanese patients, particularly those with EO‐CRC, show the highest prevalence worldwide, approximately 50%. Mechanistically, colibactin alkylates adenines within AT‐rich motifs, producing interstrand crosslinks that collapse replication forks and generate double‐strand breaks, thereby generating driver mutations in APC , TP53 , and BRAF . Notably, this mutational imprinting appears to occur predominantly early in life, whereas carcinogenesis manifests decades later, revealing a striking temporal gap between colibactin exposure and tumor onset. This review integrates global epidemiological and genomic data with the chronology of pks + bacteria to explain the spread of colibactin‐induced CRC in Japan, particularly among younger people. These insights may ultimately inform new strategies for the prevention and early detection of EO‐CRC.

doi.org/10.1111/cas.70590Open accessPubMed 43040938Mechanisms

AgingResearch.News